Advertisement
Advertisement
U.S. markets close in 3 hours 40 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Salarius Pharmaceuticals, Inc. (SLRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2329-0.0051 (-2.14%)
As of 12:18PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close0.2380
Open0.2407
Bid0.2330 x 800
Ask0.2336 x 800
Day's Range0.2250 - 0.2407
52 Week Range0.1600 - 1.2000
Volume90,852
Avg. Volume891,016
Market Cap13.069M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-0.3770
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SLRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Salarius Pharmaceuticals, Inc.
    CYTK: Raising target price to $50.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $50.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

    Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00 a.m. ETHOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and

  • GlobeNewswire

    Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

    Clinical Trial Now Expands to Fifteen U.S. Trial SitesHOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the addition of four prestigious institutions to the open-label Phase 1/2 trial with seclidemstat in Ewing’s sarcoma and FET-rearranged sarcomas. The Seattle Cancer Care Alliance (SCCA) – which is comprised of the Fred Hutc

  • GlobeNewswire

    Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

    HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, today announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q® technology to support further development of Salarius’ clinical stage d

Advertisement
Advertisement